July 18, 2017 / 12:45 PM / 2 years ago

BRIEF-Delmar Pharmaceuticals reports completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory GBM

July 18 (Reuters) - Delmar Pharmaceuticals Inc:

* Delmar Pharmaceuticals announces completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory gbm

* Delmar Pharmaceuticals Inc - Delmar anticipates initiation of additional centers and commencement of treatment under star-3 protocol in coming weeks Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below